🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Dr. Mohit Khera spoke with Urology Times about the impacts of the penile prosthesis on mental health. Listen and watch at bit.ly/3Fw1uQk #BCMUrology #MensHealth #PenileProsthesis

Roshan Patel, MD, (Roshan Patel, MD) highlights a study assessing the impact of saline restrictions on PCNL outcomes. #AUA25 UCI Urology UCI Kidney Stone Center urologytimes.com/view/roshan-pa…

Paclitaxel eluting bioabsorbable implants demonstrated encouraging efficacy and appeared to be safe and feasible in the treatment of patients with BPH-related LUTS. #urology urologytimes.com/view/intrapros…

Explore the impact of GEMTESA® (vibegron) in our upcoming live national broadcast! Hear expert insights, review phase 3 COURAGE trial data, and get a patient’s perspective. Register now: bit.ly/45bfs4A Please see full Prescribing Information. bit.ly/4j3ZGvG

#ASCO25 kicks off today! Sign up🔓 to view our preview of notable abstracts in GU oncology: urologytimes.com/view/asco-2025…

In a recent interview with Urology Times, Andrew Armstrong, MD, (Andrew Armstrong) of Duke Urology previewed key prostate cancer data to look out for ahead of #ASCO25. Listen to his insights here: urologytimes.com/view/andrew-ar…

ORIC-944, in combination with AR inhibitors, elicited promising clinical activity in patients with mCRPC, according to data from a phase 1b trial. #pcsm urologytimes.com/view/oric-944-…

The first patient has been dosed in the phase 2a LEGION-100 trial, evaluating SYNC-T therapy SV-102 in patients with mCRPC. #pcsm Jason Hafron urologytimes.com/view/phase-2-t…

PEACE-3 data for radium-223/enzalutamide published in Annals of Oncology urologytimes.com/view/peace-3-d… #urology #pcsm #prostatecancer

Day 2 of #ASCO25 is underway! Professor Dickon Hayne offers his thoughts on exciting areas of ongoing development within bladder cancer. Stay tuned for his insights on a phase 3 trial of mitomycin plus BCG in high-risk NMIBC. #blcsm urologytimes.com/view/professor…

📢 #ASCO25 | AREN1721 Ph. II | tRCC Trial: Nivo + axi (6 pts) in advanced tRCC: PR 33% vs 0% in mono arms (2pts axi and 5 nivo); With axitinib addition PFS increased from 1.8 → 10.5 mo , OS improved as well. 9/13 age < 18 years. No unexpected toxicities. Rare but aggressive

CLONEVO: Preoperative abemaciclib (CDK4/6 inhibitor) in cisplatin ineligible MIBC(n=20) pCR= 18% seems modest. RB1 phosphorylation confirmed on-target activity. Serial ctDNA showed 27% ⬇️ in TF. Great biomarker work showing suppression of E2F-dependent cell proliferation #ASCO25

Interim results from the phase 3 ENLIGHTED trial indicate that padeliporfin vascular targeted photodynamic therapy is safe and efficacious in the management of low-grade upper tract urothelial cancer. #ASCO25 UT Southwestern Urology urologytimes.com/view/interim-e…

📢 #ASCO25 | ANZUP 1301 Ph III | HR NMIBC (~500 pts): Mitomycin + BCG vs BCG alone—combination arm met primary endpoint with significant DFS benefit (HR 0.70; 2‑yr DFS 78% vs 65%); recurrence reduced. Dickon Hayne et al. Full abstract → asco.org/abstracts-pres…

Adjuvant pembrolizumab continued to show consistent OS and DFS benefits vs placebo for patients with clear cell renal cell carcinoma (#ccRCC), according to a landmark 5-year analysis of the phase 3 KEYNOTE-564 study. #ASCO25 urologytimes.com/view/adjuvant-…

Long-term results of the REASSURE trial support the safety of radium-223 in patients with mCRPC. #ASCO25 Oliver J. Sartor urologytimes.com/view/long-term…

Lower-dose abiraterone demonstrated comparable efficacy to standard-dose abiraterone, positioning itself as a viable alternative for patients with mCRPC, according to data presented at #ASCO25. | Minit Shah urologytimes.com/view/lower-dos…

The phase 3 PSMAddition trial has met its primary end point, showing that lutetium (177Lu) vipivotide tetraxetan plus SOC significantly improved rPFS vs SOC alone in patients with PSMA-positive mHSPC. #pcsm urologytimes.com/view/adding-lu…